Current stock page

Stock Analysis

Vaxcyte, Inc. (PCVX) Stock Analysis

Vaxcyte, Inc. (PCVX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PCVX Stock Analysis Summary

Vaxcyte, Inc. (PCVX) currently has an AIQ Score of 66/100, indicating a bullish setup. Momentum is the strongest factor at 81/100. Risk is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

PCVX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$63.37
AIQ Score66/100
Overall ViewBullish
Technical Analysis ConsensusNeutral
Market Cap$9.44B
P/E Ratio (TTM)-7.85
Forward P/E—
EPS (Q3 FY2026)-$1.99
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.26
Volume623.63K
52-week range$42.40-$90.75
RSI 1449.5
50-Day SMA$62.24
200-Day SMA$57.70
Analyst Price Target$122.33
Next EarningsFeb 23, 2027
As of Nov 13, 2026 · Market close

PCVXVaxcyte, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$63.37−$1.32 (−2.04%)

Latest quote

  • Momentum
    81
  • Value
    —
  • Quality
    54
  • Risk resilience
    53
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

PCVX Stock Analysis Summary

Vaxcyte, Inc. (PCVX) currently has an AIQ Score of 66/100, indicating a bullish setup. Momentum is the strongest factor at 81/100. Risk resilience is the weakest current factor at 53/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, PCVX has AIQ Score of 66/100 with Momentum base of 81/100 and fading Risk resilience at 53/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (81/100) leads while Risk resilience (53/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.04% stock move · PCVX classified in Biotechnology.

Current Evidence

BullishPCVX is in a bullish AIQ regime; Momentum is the strongest visible factor at 81/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PCVX Bullish or Bearish Right Now?

PCVX currently has a bullish overall setup. Momentum is the strongest factor at 81/100, while Risk Resilience is weakest at 53/100. The current evidence suggests a constructive setup.

Bull Case
  • - Momentum is constructive at 81/100.
  • - Price is +1.82% above its 50-day SMA.
  • - Analyst target implies +93.05% upside from the latest quote.
Bear Case
  • - Technical consensus has more sell votes than buy votes (19 vs 17).

Current Consensus

PCVX's Technical Analysis Consensus is currently Neutral, with 17 buy, 10 neutral, and 19 sell votes. PCVX's 14-day RSI is 49.5, which places the stock in a neutral momentum range. PCVX's beta is 1.26, indicating greater market sensitivity than the broad market.

Signal Confidence
Moderate agreement

What Changed in PCVX?

The largest recent change in PCVX is Risk Resilience moving down by 1.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+0.0
Momentum
+0.0
Quality
+0.0
Risk
-1.0

What Would Change the PCVX Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PCVX Decision Framework

Public evidence layers, setup checks, and risk context for Vaxcyte, Inc..

Vaxcyte, Inc. (PCVX) Stock Analysis

Vaxcyte, Inc. has an AIQ Score of 66/100 in a Bullish regime. Momentum is strongest at 81/100. Beta is 1.26, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPCVX is in a Bullish AIQ regime with score 66/100.
Signal ConflictThe primary conflict is that momentum leads at 81/100 while risk lags at 53/100.
Factor EvidenceMomentum 81/100 · Quality 54/100 · Risk 53/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 81/100.

TimingPass

Momentum is 81/100 and RSI (14) is 49.5.

Regime fitPass

PCVX is in a Bullish regime at 66/100.

Risk controlWait

Risk factor is 53/100 with beta 1.26 and annual volatility 56.19%.

ConflictWait

Current conflict: momentum leads at 81/100 while risk lags at 53/100.

AIQ Score
66/100
Price
$63.37
Beta
1.26
RSI (14)
49.5

PCVX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PCVX Fundamentals

PCVX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$297.06M
Free cash flow
-$229.04M
View full PCVX fundamental analysis

PCVX Technical Analysis

PCVX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Neutral
RSI 14
49.5
Price vs SMA-50
+1.82%
View full PCVX technical analysis

PCVX Stock Catalysts

Track PCVX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 23, 2027
Analyst target
$122.33
News items
5
View PCVX earnings and stock catalysts

PCVX Dividend Analysis

PCVX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View PCVX dividend history and analysis

PCVX Financial Data

PCVX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$1.99
Periods
8
View PCVX financials

PCVX Risk Analysis

PCVX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.26
Risk score
53/100
1Y volatility
56.19%
View PCVX risk analysis

PCVX Stock News

PCVX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read PCVX stock news

PCVX vs Biotechnology Peers

Current peer cohort: PCVX · PGEN · PRAX · PTGX · PVLA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PCVX
Current stock
66/100—81/10053/1000.7956.19%Current
PGEN
Precigen, Inc.
55/10063/10055/10031/1000.5785.43%PCVX vs PGEN
PRAX
Praxis Precision Medicines, Inc.
57/100—48/10047/1001.1375.11%PCVX vs PRAX
PTGX
Protagonist Therapeutics, Inc.
73/10072/10070/10070/1001.2440.11%PCVX vs PTGX
PVLA
Palvella Therapeutics, Inc.
70/100—84/10047/1001.1284.47%PCVX vs PVLA
Pairwise Compare links: PGEN · PRAX · PTGX · PVLAPCVX vs PGENPCVX vs PRAXPCVX vs PTGXPCVX vs PVLACompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PCVX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for PCVX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.85
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.09
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$297.06M
Quarter free cash flow
-$229.04M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
49.5
MACD
0.75

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
53/100
Beta
1.26
Annual volatility
56.19%
Max drawdown
-27.95%

PCVX Stock FAQ

What is PCVX stock price today?

Vaxcyte, Inc.'s current stock price is $63.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PCVX bullish or bearish right now?

PCVX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PCVX's market cap?

PCVX's market cap is $9.44B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PCVX's current P/E ratio?

PCVX's current P/E ratio is -7.85 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PCVX's RSI?

PCVX's 14-day RSI is 49.5 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PCVX above its 50-day and 200-day moving averages?

PCVX is 1.82% from its 50-day SMA and 9.82% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PCVX's next earnings date?

PCVX's next earnings date is currently listed as Feb 23, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PCVX pay a dividend?

PCVX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.